14.1 The Eleven Current GCP Principles

The Eleven Current GCP Principles

The global architecture of clinical trial regulation rests upon the standards established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). For the professional Clinical Research Associate (CRA), Good Clinical Practice is not merely an abstract regulatory ideal; it is the operational playbook that governs every site assessment, document review, and data verification activity conducted in the field.

The current 11-principle framework

E6(R3) groups GCP into eleven main principles. Read their subprinciples together rather than treating a numbered slogan as the answer to every scenario.

The old thirteen-principle R2 list is not the current numbering. More importantly, R3 makes quality, proportionality, fit-for-purpose systems and clear responsibilities explicit. A detailed checklist cannot compensate for a design that creates avoidable participant burden or fails to measure the primary outcome reliably.

Consider a study with frequent assessments that do not answer its objectives. Quality by design asks whether those assessments are necessary and feasible before initiation. Removing unnecessary procedures through the authorised design process can reduce burden and error. A site cannot simply omit them after initiation: proportionate quality management must operate through the protocol and controlled change process.

Consider an electronic data transfer that faithfully copies an incorrect field mapping. A successful transfer count does not establish reliable results. The team needs suitable mapping, validation/reconciliation, relevant metadata and review of critical outputs. The CRA contributes by recognising clinical inconsistencies, verifying the site process and escalating a system defect to the responsible function.

Consider a sponsor that transfers monitoring to a service provider. A contract clarifies activities but does not eliminate sponsor oversight. Similarly, an investigator can delegate a qualified coordinator's work but remains responsible for site oversight. Establish who acts, who reviews, what evidence is retained and where concerns are escalated.

Navigating the current guideline

The final E6(R3) Principles and Annex 1 were adopted at ICH Step 4 on January 6, 2025. ACRP's current CCRA reference links to that document. Use Annex 1 for IRB/IEC, investigator, sponsor and data governance responsibilities. Appendix A concerns the IB, Appendix B the protocol, and Appendix C essential records. An old reference such as R2 section 4.8 should not be relabelled as the same number in R3.

The principles apply across suitable trial approaches; Annex 1 is not a prohibition on remote interactions or electronic information. Assess which activities and technologies are appropriate to the trial and how participant protection, oversight, access and data reliability are maintained. Do not assume that an additional or future annex is part of the certification reference merely because it has been announced or published. Confirm ACRP's linked reference list for the test period.

E6(R3) distinguishes guidance from applicable regulatory requirements. In real trial conduct both matter. On the CCRA exam, ACRP specifies its international ICH reference framework rather than FDA form numbers or country-specific portals. When a task example mentions a local concept, practise the underlying decision: verify an investigator's standing, protect privacy, document a safety report or confirm authorisation.

A proportionate approach requires justification, not reduced care. A high-risk first-in-human dose process may need intensive oversight. A lower-risk process may use fewer manual checks when validated controls and central surveillance provide adequate assurance. Document the rationale, examine experience and adjust controls when new information changes risk.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ACRP CCRA Exam Content Outline.